Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy

Outcomes for metastatic melanoma patients treated with checkpoint blockade were poor when circulating Ang-2 was high. Ang-2 promoted recruitment of tumor macrophages and upregulated PD-L1, making it a predictive and/or prognostic biomarker and potential target to combine with checkpoint blockade. Immune checkpoint therapies targeting CTLA-4 and PD-1 have proven effective in cancer treatment. However, the identification of biomarkers for predicting clinical outcomes and mechanisms to overcome resistance remain as critical needs. Angiogenesis is increasingly appreciated as an immune modulator with potential for combinatorial use with checkpoint blockade. Angiopoietin-2 (ANGPT2) is an immune target in patients and is involved in resistance to anti-VEGF treatment with the monoclonal antibody bevacizumab. We investigated the predictive and prognostic value of circulating ANGPT2 in metastatic melanoma patients receiving immune checkpoint therapy. High pretreatment serum ANGPT2 was associated with reduced overall survival in CTLA-4 and PD-1 blockade–treated patients. These treatments also increased serum ANGPT2 in many patients early after treatment initiation, whereas ipilimumab plus bevacizumab treatment decreased serum concentrations. ANGPT2 increases were associated with reduced response and/or overall survival. Ipilimumab increased, and ipilimumab plus bevacizumab decreased, tumor vascular ANGPT2 expression in a subset of patients, which was associated with increased and decreased tumor infiltration by CD68+ and CD163+ macrophages, respectively. In vitro, bevacizumab blocked VEGF-induced ANGPT2 expression in tumor-associated endothelial cells, whereas ANGPT2 increased PD-L1 expression on M2-polarized macrophages. Treatments elicited long-lasting and functional antibody responses to ANGPT2 in a subset of patients receiving clinical benefit. Our findings suggest that serum ANGPT2 may be considered as a predictive and prognostic biomarker for immune checkpoint therapy and may contribute to treatment resistance via increasing proangiogenic and immunosuppressive activities in the tumor microenvironment. Targeting ANGPT2 provides a rational combinatorial approach to improve the efficacy of immune therapy. Cancer Immunol Res; 5(1); 17–28. ©2016 AACR.

[1]  A. Giobbie-Hurder,et al.  VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma , 2016, Cancer Immunology Research.

[2]  Jennie W. Taylor,et al.  Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival , 2016, Proceedings of the National Academy of Sciences.

[3]  R. Jain,et al.  Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages , 2016, Proceedings of the National Academy of Sciences.

[4]  K. Plate,et al.  Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma , 2015, EMBO molecular medicine.

[5]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[6]  Y. Reiss,et al.  Angiopoietin‐2: a multifaceted cytokine that functions in both angiogenesis and inflammation , 2015, Annals of the New York Academy of Sciences.

[7]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[8]  G. Bergers,et al.  Intertwined regulation of angiogenesis and immunity by myeloid cells. , 2015, Trends in immunology.

[9]  G. Freeman,et al.  The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. , 2015, Clinical therapeutics.

[10]  G. Natoli,et al.  Macrophages and cancer: from mechanisms to therapeutic implications. , 2015, Trends in immunology.

[11]  D. Jäger,et al.  Association of angiogenic factors with prognosis in esophageal cancer , 2015, BMC Cancer.

[12]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[13]  J. Wolchok,et al.  Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Borg,et al.  Prognostic Value of Angiopoietin-2 for Death Risk Stratification in Patients with Metastatic Colorectal Carcinoma , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[15]  Elise Langenkamp,et al.  VEGF suppresses T‐lymphocyte infiltration in the tumor microenvironment through inhibition of NF‐κB‐induced endothelial activation , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  Kshitij Srivastava,et al.  Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. , 2014, Cancer cell.

[17]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[18]  R. Beelen,et al.  Human macrophage polarization in vitro: maturation and activation methods compared. , 2014, Immunobiology.

[19]  I. Keklikoglou,et al.  Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. , 2014, Cell reports.

[20]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[21]  X. Mo,et al.  Macrophage Colony-Stimulating Factor Augments Tie2-Expressing Monocyte Differentiation, Angiogenic Function, and Recruitment in a Mouse Model of Breast Cancer , 2014, PloS one.

[22]  A. D. Van den Abbeele,et al.  Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma , 2014, Cancer Immunology Research.

[23]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Orekhov,et al.  Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis , 2014, Front. Physiol..

[25]  S. Gordon,et al.  The M1 and M2 paradigm of macrophage activation: time for reassessment , 2014, F1000prime reports.

[26]  J. Wolchok,et al.  Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab , 2014, Cancer Immunology Research.

[27]  P. Tak,et al.  Tie2 Signaling Cooperates with TNF to Promote the Pro-Inflammatory Activation of Human Macrophages Independently of Macrophage Functional Phenotype , 2014, PloS one.

[28]  J. Quigley,et al.  Angiogenic capacity of M1- and M2-polarized macrophages is determined by the levels of TIMP-1 complexed with their secreted proMMP-9. , 2013, Blood.

[29]  Y. Kienast,et al.  Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy , 2013, Clinical Cancer Research.

[30]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[31]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[32]  C. Lewis,et al.  Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.

[33]  F. Hodi,et al.  Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma , 2013, PloS one.

[34]  Y. Kienast,et al.  A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors , 2013, PloS one.

[35]  G. Thurston,et al.  The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway. , 2012, Cold Spring Harbor perspectives in medicine.

[36]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[37]  G. Dranoff,et al.  Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.

[38]  E. Chavakis,et al.  Angiopoietin-2 promotes myeloid cell infiltration in a β₂-integrin-dependent manner. , 2011, Blood.

[39]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[40]  L. Naldini,et al.  Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. , 2011, Cancer cell.

[41]  Janet Do,et al.  Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth , 2011, Clinical Cancer Research.

[42]  Donna Neuberg,et al.  Active immunotherapy induces antibody responses that target tumor angiogenesis. , 2010, Cancer research.

[43]  H. Augustin,et al.  Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy , 2010, British Journal of Cancer.

[44]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[45]  S. Rosenberg,et al.  Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. , 2010, Cancer research.

[46]  Abhijit Bhat,et al.  Targeting the ANGPT–TIE2 pathway in malignancy , 2010, Nature Reviews Cancer.

[47]  K. Plate,et al.  Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. , 2010, Cancer research.

[48]  Alberto Mantovani,et al.  Macrophages, innate immunity and cancer: balance, tolerance, and diversity. , 2010, Current opinion in immunology.

[49]  R. Herbst,et al.  Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Jing Xu,et al.  Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1 , 2009, The Journal of experimental medicine.

[51]  D. Schadendorf,et al.  Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma , 2009, Clinical Cancer Research.

[52]  H. Augustin,et al.  Angiopoietins: a link between angiogenesis and inflammation. , 2006, Trends in immunology.

[53]  C. Tait,et al.  Angiopoietins in tumours: the angiogenic switch , 2004, The Journal of pathology.

[54]  John O'Quigley,et al.  An application of changepoint methods in studying the effect of age on survival in breast cancer , 1999 .

[55]  D. Carbone,et al.  Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. , 1998, Journal of immunology.

[56]  Alastair H Kyle,et al.  Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. , 2013, Cancer research.

[57]  D. Carbone,et al.  VEGF as a mediator of tumor-associated immunodeficiency , 2001, Immunologic research.